Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
2018 · New England Journal of Medicine · 2,100 citations
https://doi.org/10.1056/nejmoa1716078
S
Stephen Broderick
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
183
Papers
12.6K
Citations
39
h-index
78
i10-index
Stephen Broderick is an academic researcher from Bloomberg (United States). The author has contributed to research in topics: Lung Cancer Diagnosis and Treatment & Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers. The author has an h-index of 39, co-authored 156 publications.
ORCID: 0000-0001-5905-4714Papers by this author
works<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib
2007 · Proceedings of the National Academy of Sciences · 1,582 citations
https://doi.org/10.1073/pnas.0710370104
Adjuvant and Neoadjuvant Immunotherapy in Non–small Cell Lung Cancer
2020 · Thoracic surgery clinics/Thorac. surg. clin. · 109 citations
https://doi.org/10.1016/j.thorsurg.2020.01.001
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
2025 · New England Journal of Medicine · 75 citations
https://doi.org/10.1056/nejmoa2502931
SCCRO Promotes Glioma Formation and Malignant Progression in Mice
2010 · Neoplasia · 35 citations
https://doi.org/10.1593/neo.10202
Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i> Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
2024 · Clinical Cancer Research · 9 citations
https://doi.org/10.1158/1078-0432.ccr-24-2983
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat